(702) 683-8946

Monday - Friday 9am to 5pm



Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)



CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform




Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business


Latest News Releases From The Newsroom

Anticipation Builds as Prominent Companies Prepare to Report Earnings: Ulta Beauty, Best Buy, Deckers Outdoor, Burlington Stores, Ralph Lauren

May 22nd, 2023

Ulta Beauty, Inc. (Nasdaq: ULTA) is scheduled to unveil its first-quarter earnings for the period ending April 29, 2023, after the market closes. Analysts have a consensus earnings per share (EPS) estimate of $6.86 on revenue of $2.62 billion. On Mon. Read more

TEGNA Announces Shareholder-Focused Moves; Applied UV and RYVYL Report Impressive Q1 Revenue Growth

May 22nd, 2023

TEGNA Inc. (NYSE: TGNA) has announced significant measures to return excess capital to its shareholders. The company has initiated a $300 million accelerated share repurchase program and increased its quarterly dividend by 20 percent. These actions f. Read more

Earnings Surpass Estimates: Nordson and Zoom Video Lead, Rubicon Technologies Beats Loss Expectations, Kaspien Holdings to Delist Stock

May 22nd, 2023

Nordson Corporation (Nasdaq: NDSN) has released its second quarter fiscal 2023 earnings per share (EPS) of $2.26, surpassing the consensus estimate of $2.11. The company is maintaining its previously issued guidance for full-year revenue growth, expe. Read more

Eagerly Awaited Financial Reports: Costco, Royal Bank of Canada, Toronto-Dominion Bank, NetEase, and Dollar Tree

May 22nd, 2023

Several prominent companies are set to release their financial results on Thursday, May 25. Costco Wholesale Corporation (Nasdaq: COST) is scheduled to announce its third-quarter fiscal 2023 financial results after the market closes. The consensus. Read more

FTC Suit Leads to $16.7 Million Judgment Against Principals and Celebrity Endorsers of Real Estate Investment Training Program

May 22nd, 2023

Court order agreed to by principals permanently bans them from selling “wealth creation” programs Washington D.C. / CRWE PRESS RELEASE / May 22, 2023 -  As a result of a lawsuit filed by the Federal Trade Commission and the U. Read more

Stock Market Buzz: Notable Upgrades Boost AnaptysBio, Avidity Biosciences, Corteva, Knight-Swift Transportation, and KeyCorp

May 22nd, 2023

Several notable upgrades have been observed in the stock market today.  AnaptysBio, Inc. (Nasdaq: ANAB) experienced an upgrade from Underweight to Neutral by JP Morgan. This upgrade reflects a more positive outlook on the company's perfor. Read more

Notable Upgrades and Initiations Propel Stocks Higher: DraftKings, Azul, TrueBlue, DICE Therapeutics, Progyny

May 22nd, 2023

In the latest market updates, several notable upgrades and initiations have taken place among various companies. DraftKings Inc. (Nasdaq: DKNG) received an upgrade from Neutral to Buy at UBS, with the price target raised from $19 to $30. This posi. Read more

Freeline Therapeutics Receives Innovation Passport for Gaucher Disease Drug; Rain Oncology's Clinical Trial Disappoints; Chevron Expands with PDC Energy Acquisition

May 22nd, 2023

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) has made an important announcement regarding its drug FLT201. The company revealed that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease type 1 under the Innovative. Read more

Hepion Pharmaceuticals' Promising Clinical Trial Results Drive Stock Surge; Apple Faces Downgrade; Plug Power Secures Groundbreaking Green Hydrogen Projects

May 22nd, 2023

Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) has delivered promising news with the announcement of positive topline results from its recently completed Phase 2 ALTITUDE-NASH clinical trial. The trial successfully met its primary endpoint by demonstrat. Read more

AVROBIO Sells Cystinosis Therapy Program to Novartis, Stock Surges; Compass Minerals Inks Lithium Supply Deal with Ford; Global-e Online Beats Estimates, Stock Declines

May 22nd, 2023

AVROBIO, Inc. (Nasdaq: AVRO) has made a significant announcement, revealing that it has entered into an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis (NYSE: NVS). . Read more